Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjd.20569 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
Future Oncol
January 2025
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults with locally advanced or metastatic BCC who are not candidates for surgery or radiation therapy is treatment with hedgehog pathway inhibitors (HHIs). For patients who progress while on this therapy, further treatment options are limited.
View Article and Find Full Text PDFDisparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis.
JCO Oncol Adv
December 2024
Department of Epidemiology, University of Florida College of Public Health and Health Professions, Gainesville, FL.
Purpose: In the United States, there are disparities in access to care for patients with non-small cell lung cancer (NSCLC) on the basis of socioeconomic and racial/ethnic factors. This study investigates the association between race/ethnicity and the utilization of immune checkpoint inhibitor (ICI) therapy among older patients with advanced NSCLC (aNSCLC).
Methods: This retrospective study used data from the SEER-Medicare-linked database.
Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma.
J Immunother Precis Oncol
August 2024
Medical College of Wisconsin, Milwaukee, WI, USA.
A 62-year-old man presented with a slowly growing, painless lesion on his face. This eventually led to a progressive left-eye vision lesion, and the patient was subsequently diagnosed with advanced basal cell carcinoma (BCC). Of note, BCC involving cranial nerves is extremely rare, making this case unique and important to highlight.
View Article and Find Full Text PDFLibtayo (cemiplimab-rwlc) injection for intravenous use was recently approved by the US Food and Drug Administration (FDA) for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC), both being the advanced stages of BCC. In the past, it was approved by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC), both being the advanced stages of CSCC. Cemiplimab is a monoclonal antibody that works by blocking the programmed death-1 pathway.
View Article and Find Full Text PDFQuality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.
Future Oncol
October 2024
Mayo Clinic, Scottsdale, AZ 85259, USA.
Article Synopsis
- The study assessed health-related quality of life (HRQoL) in 84 patients with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab.
- Patients received cemiplimab every 3 weeks for up to 9 cycles, and HRQoL was evaluated using the QLQ-C30 and Skindex-16 questionnaires at various points.
- Results showed that 62-90% of patients experienced improvement or maintenance in HRQoL, except for fatigue, which remained a concern throughout the treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!